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PSTATE-OF-THE-ART PAPER2465Myocardial Recovery and the Failing HeartDouglas L. Mann, Philip M. Barger, Daniel Burkhoff
Medical and device therapies that reduce heart failure morbidity and mortality also lead to
decreased left ventricular volume and mass, and a more normal elliptical shape of the
ventricle. These are due to changes in myocyte size, structure, and organization that have
been referred to collectively as “reverse remodeling.” Despite the frequent interchangeable use
of the terms myocardial recovery and reverse remodeling, Mann and colleagues propose that
there are important differences between these 2 phenomenon. They discuss the biology of
cardiac remodeling, cardiac reverse remodeling, and myocardial recovery, with the intent of
providing a conceptual framework for understanding myocardial recovery.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2473Drug-Eluting Balloon May Be Superior to DES for Small VesselsAzeem Latib, Antonio Colombo, Fausto Castriota, Antonio Micari, Alberto Cremonesi, Francesco De Felice,
Alfredo Marchese, Maurizio Tespili, Patrizia Presbitero, Gregory A. Sgueglia, Francesca Buffoli,
Corrado Tamburino, Ferdinando Varbella, Alberto Menozzi
Latib and colleagues randomized 182 patients with coronary stenoses in small vessels
(reference diameter 2.8mm) to treatment with a paclitaxel drug-eluting balloon (DEB) and
rovisional bare-metal stenting (BMS) or paclitaxel-eluting stent (PES) implantation. The
rimary endpoint of in-stent (in-balloon) late loss was significantly lower with DEB. At 6
onths, DEB and PES were associated with similar rates of angiographic restenosis, target
esion revascularization, and MACE. These results suggest that DEB may be superior to
ES for interventions in small vessels.(continued on page A-26)
DECEMBER 18, 2012 (continued) A-26INTERVENTIONAL CARDIOLOGY2481Improved Outcomes With Radial Access for STEACSEnrico Romagnoli, Giuseppe Biondi-Zoccai, Alessandro Sciahbasi, Luigi Politi, Stefano Rigattieri,
Gianluca Pendenza, Francesco Summaria, Roberto Patrizi, Ambra Borghi, Cristian Di Russo,
Claudio Moretti, Pierfrancesco Agostoni, Paolo Loschiavo, Ernesto Lioy, Imad Sheiban, Giuseppe Sangiorgi
The RIFLE trial compared outcomes in 1,000 ST-segment elevation acute coronary
syndrome (STEACS) patients undergoing primary/rescue percutaneous coronary intervention.
The primary endpoint was the 30-day rate of net adverse clinical event (NACE) (defined as
composite of cardiac death, stroke, myocardial infarction, target lesion revascularization, and
bleeding) was 14% in the radial arm and 21% in the femoral arm. Radial access was
associated with significantly lower rates of cardiac mortality, bleeding, and shorter hospital
stays. Radial access in patients with STEACS is associated with significant clinical benefits, in
terms of both lower morbidity and cardiac mortality.INTERVENTIONAL CARDIOLOGY
2490Effects of Radial Versus Femoral Artery
Access in Patients With ACS With or Without STEMIShamir R. Mehta, Sanjit S. Jolly, John Cairns, Kari Niemela, Sunil V. Rao, Asim N. Cheema,
Philippe Gabriel Steg, Warren J. Cantor, Vladimı´r Džavı´k, Andrzej Budaj, Michael Rokoss,
Vicent Valentin, Peggy Gao, Salim Yusuf
The RIVAL Trial randomized patients with ST-segment elevation myocardial infarction
(STEMI) and non-ST-segment elevation acute coronary syndrome (NSTEACS) to radial or
femoral access for their angiography. In STEMI patients, radial access reduced the primary
outcome of death/MI/stroke/non-CABG-related major bleeding compared with femoral
access (3.1% vs 5.2%). For NSTEACS, the rates were not different. In STEMI patients,
death/MI/stroke was also reduced with radial access, as was all-cause mortality, with again no
difference in NSTEACS patients. This trial confirms the benefits of radial access for STEMI
patients, but no evidence that it benefits lower risk NSTEACS patients.Editorial Comment: Olivier F. Bertrand, Tejas Patel, page 2500HEART FAILURE2504High Incidence of HF or CM After Trastuzumab Therapy for Breast CancerJersey Chen, Jessica B. Long, Arti Hurria, Cynthia Owusu, Richard M. Steingart, Cary P. Gross
Chen and colleagues used Medicare data to estimate heart failure (HF) and cardiomyopathy
(CM) rates following chemotherapy and adjuvant trastuzumab in older women for breast
cancer. Almost 50,000 women age 67 to 94 years with early-stage breast cancer were
identified. Adjusted 3-year HF/CM incidence rates were higher for patients receiving
trastuzumab (32 per 100 patients) and anthracycline plus trastuzumab (42 per 100 patients)
compared with no adjuvant therapy (18 per 100 patients). These results show that at least
one-third of elderly women.
Editorial Comment: Daniel J. Lenihan, page 2513(continued on page A-27)
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2515Measuring Vagal Reflexes Following Exercise Stress Test
May Improve Risk Stratification in Patients With Long QT SyndromeLia Crotti, Carla Spazzolini, Alessandra P. Porretta, Federica Dagradi, Erika Taravelli, Barbara Petracci,
Alessandro Vicentini, Matteo Pedrazzini, Maria Teresa La Rovere, Emilio Vanoli, Althea Goosen,
Marshall Heradien, Paul A. Brink, Alfred L. George Jr., Peter J. Schwartz
Crotti and colleagues have previously shown that depressed baroreflex sensitivity (BRS), a
marker of reduced vagal reflexes, predicts the risk of symptoms in long QT syndrome
(LQTS) type 1 (LQT1) patients. For this report, they assessed the utility of another marker
of vagal refelxes, heart rate recovery after exercise. Data was obtained from LQTS genotype-
positive patients who performed an exercise stress test. Despite similar maximal heart rate and
workload, the symptomatic patients LQTS1 patients had a greater heart rate (HR) reduction
in the first minute after exercise compared to the asymptomatic. There was no difference in
HR recovery in LQT2 and LQT3 patients stratifed by symptoms. These results suggest that
heart rate recovery after exercise may be useful for risk stratification in LQT1 patients.Editorial Comment: Koonlawee Nademanee, page 2525CARDIAC IMAGING2527PET/CT Imaging of Cardiac Angiotensin II Type 1 ReceptorsKenji Fukushima, Paco E. Bravo, Takahiro Higuchi, Karl H. Schuleri, Xiaoping Lin, M. Roselle Abraham,
Jinsong Xia, William B. Mathews, Robert F. Dannals, Albert C. Lardo, Zsolt Szabo, Frank M. Bengel
Fukushima and colleagues explored the feasibility of targeted imaging of the angiotensin II
subtype 1 receptor (AT1R) in cardiac tissue using hybrid positron emission tomography/
computed tomography (PET/CT) and a novel AT1R ligand. PET/CT was performed in
healthy pigs and pigs 3 to 4 weeks after experimental myocardial infarction. In healthy pigs,
AT1R expression was regionally homogeneous. After myocardial infarction, AT1R was
upregulated in the infarct area relative to remote myocardium, and elevated in both regions
compared to healthy hearts. First-in-man application was safe, and showed detectable and
specific myocardial retention of the AT1R ligand. Noninvasive imaging of cardiac AT1R
expression is feasible using PET/CT technology.
Editorial Comment: Thomas H. Schindler, Vasken Dilsizian, page 2535(continued on page A-28)
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EBIOMARKERS2539Moderate Physical Activity Appears to Protect Against HFChristopher R. deFilippi, James A. de Lemos, Andrew T. Tkaczuk, Robert H. Christenson,
Mercedes R. Carnethon, David S. Siscovick, John S. Gottdiener, Stephen L. Seliger
deFilippi and colleagues evaluated the association between physical activity and serum levels
f highly sensitive troponin T (cTnT) and amino-terminal B-type natriuretic peptide (NT-
roBNP), along with the subsequent risk of heart failure (HF). Compared to participants
ith the lowest physical activity (on a scale of 1 to 7), those with the highest were only one-
alf as likely to have a significant rise in NT-proBNP and one-third as likely to have a rise in
TnT. A higher activity score was also associated with a lower long-term incidence of HF.
hese findings suggest that moderate physical activity has protective effects on early HF
henotypes.ditorial Comment: Christopher M. O’Connor, Tariq Ahmad, page 2548PRE-CLINICAL RESEARCH2550Targeted Thrombolysis With Novel Drug Delivery Systemzinc acetate (5 mM)
nanoparticle (NP)
(100-150 nm)
tPA releasing
tPA (0.5 mg/ml)
basic gelatin 
(10 mg/ml)
tPA-gelatin complex
US (1 MHz, 1 W/cm2)Hiroyuki Kawata, Yoshiko Uesugi, Tsunenari Soeda, Yasuhiro Takemoto, Ji-Hee Sung, Kiyotaka Umaki,
Keiji Kato, Kenichi Ogiwara, Keiji Nogami, Kenichi Ishigami, Manabu Horii, Shiro Uemura, Midori Shima,
Yasuhiko Tabata, Yoshihiko Saito
Kawata and colleagues recently produced nanoparticles composed of tissue-type plasminogen
activator (tPA), basic gelatin, and zinc ions. This formulation suppresses tPA activity by 50%,
but full tPA activity can be restored with ultrasound (US) disruption of the particles. In a
mouse arterial thrombosis model, the nanoparticles were confirmed to bind to von Willebrand
factor (vWF), and preferentially accumulate at the site of thrombus. In a swine acute
myocardial infarction (AMI) model, plasma tPA activity after intravenous injection of
nanoparticles was about 25% of tPA prior to US application. During US application, plasma
tPA activity near the affected coronary artery was higher than the femoral artery. This drug
delivery system may improve intravenous coronary thrombolysis without increasing the risk of
bleeding.Editorial Comment: Tomoko Ichiki, John C. Burnett, Jr., page 2558
